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transduced cells using stereological analysis of mCherry-immunolabeled cells. We found a 48 greater number of immunolabeled neurons in monkeys that displayed CNO-induced behavioral 49 impairment after DREADD transduction compared to monkeys that showed no behavioral effect 50 after CNO. Even in monkeys that showed reliable effects of CNO on behavior after DREADD 51 transduction, the number of prefrontal neurons transduced with DREADD receptor was on the 52 order of 3% of total prefrontal neurons counted. This level of histological analysis facilitates our 53 understanding of behavioral effects, or lack thereof, after DREADD vector injection in monkeys. 54
Introduction 79
Chemogenetic techniques such as DREADDs (Designer Receptors Exclusively Activated by 80 Designer Drugs) allow for the remote manipulation of neuronal activity. They can be targeted to 81 distinct cell populations defined by anatomical, connectional, or other phenotypic characteristics 82 and are activated by systemic administration of an otherwise inert drug (Armbruster et al., 83 2007) ; (Roth, 2016) . The most commonly used DREADD system employs the clozapine 84 metabolite clozapine-N-oxide (CNO) to activate a modified muscarinic acetylcholine receptor 85 which is no longer sensitive to acetylcholine as an agonist (Armbruster et al., 2007) . In principle, 86 CNO has no endogenous receptors or other physiological effects and is inert in the absence of 87 the DREADD receptor, and because the DREADD receptor has no endogenous ligand it is inert 88 until CNO or another DREADD actuator compound is administered. The DREADD receptor can 89 be linked to different G-protein signal transduction mechanisms, meaning that it is possible to 90 stimulate or inhibit neuronal activity via this system (Roth, 2016) . 91 92 Chemogenetic techniques would be particularly powerful if implemented in nonhuman primates. 93
They would allow for experimental designs with reversible manipulation of neuronal activity 94 across large anatomical regions that are beyond the reach of electrical or optogenetic 95 stimulation (Ohayon et al., 2013) and on time scales consistent with cognitive testing or 96 behavioral neurophysiology. The success of these techniques in modifying behavior when 97 DREADD receptors are expressed in rostromedial caudate (Nagai et al., 2016) or orbitofrontal 98 cortex (Eldridge et al., 2015) has been demonstrated. To effectively employ these technologies, 99 there is a need for studies that not only demonstrate the efficacy of DREADDs in non-human 100 primates, but also validate the technique and illustrate challenges to address in the future. Our 101 goals in the present study were twofold. First, we sought to implement DREADDs in nonhuman 102 primates in a different neocortical area, the dorsolateral prefrontal cortex (dlPFC), using a 103 sensitive behavioral probe of dlPFC function, the spatial delayed response task (Goldman and Rosvold, 1970; Bachevalier and Mishkin, 1986) . Second, upon observing variability in outcomes 105 after DREADD-bearing viral vector injections into dlPFC, we applied unbiased stereological 106 counting techniques to postmortem histological analysis of dlPFC in order to determine the 107 relationship between the extent of DREADD receptor transduction within dlPFC with the 108 magnitude of behavioral effect caused by DREADD receptor activation. As these studies 109 extended over a period of several years and additional information became available about the 110 use of chemogenetic techniques in monkeys, we incorporated additional control conditions into 111 our design. 112 113
Materials and Methods 114 115

Subjects 116
Five male rhesus macaques, denoted cases A, B, P, T, and Z, aged between 44 and 76 months 117 old and weighing 4.5 to 9.4 kg at the time of surgery, were used for this study. Monkeys were 118 socially housed indoors in single sex groups. Daily meals, consisting of a ration of monkey chow 119 and a variety of fruits and vegetables, was given within transport cages once testing was 120 completed, except on weekends when they were fed in their home cages. Within the home 121 cages water was available ad libitum. Environmental enrichment, in the form of play objects or 122 small food items, was provided daily in the home cages. All procedures were approved by the 123 Icahn School of Medicine Institutional Animal Care and Use Committee and conform to NIH 124 guidelines on the use of non-human primates in research. 125 126
Apparatus 127
Testing was performed within a Wisconsin General Testing Apparatus (WGTA). The WGTA is a 128 small enclosed testing area where the experimenter can manually interact with the monkey 129 during testing. Monkeys were trained to move from the home cage enclosure to a metal 130 transport cage, which was wheeled into the WGTA. The experimenter was hidden from the 131 monkey's view by a one-way mirror, with only the experimenter's hands visible. A sliding tray 132 with two food wells could be advanced within reach of the monkey, with a pulley-operated 133 opaque black screen that could be lowered to separate the tray from the monkey. 134
135
Behavioral Testing 136
Training on the delayed response task followed Bachevalier and Mishkin (1986) and Croxson et 137 al. (2011) . Monkeys were shown a small food reward (a peanut, M&M, raisin, or craisin, 138 depending on each monkey's preference), which was placed in one of two food wells on a test 139 tray. The left/right location of the reward across trials was always determined based on a 140 pseudorandomized, counterbalanced sequence. An opaque black screen was then lowered 141 between test tray and the monkey for a predefined delay period. The screen was subsequently 142 raised and the test tray was advanced within reach of the monkey. During initial shaping, the 143 monkeys were taught to displace a flat, gray tile covering one of the two small food wells. Once 144 monkeys readily displaced the tiles, they were advanced along three stages of training, with 24-145 30 trials per session. Once each monkey successfully completed the third stage of training to 146 criterion, experimental testing began, consisting of sessions of 24 trials. On each trial, if the 147 monkey reached for the correct well it was allowed to take the reward, otherwise the tray was 148 quickly pulled back before the monkey could reach for the other well. 149 150 For the first stage of training, both the baited and non-baited wells were covered, and the tray 151 advanced for the monkey's choice. Trials were repeated until the monkey chose correctly. The 152 second stage included a brief ("0 second") lowering of the opaque black screen between the 153 monkey and the food tray (the screen was lowered and then raised immediately) before the tray 154 was presented to the monkey for choice. Each monkey advanced from the first to the second 155 stage, and from the second to the third, after completing two consecutive sessions at 90% correct or better. The third stage was the same as the second with longer delays (1-5 s) of the 157 opaque screen. Each monkey started at a 1-s delay and was advanced to a 1-s longer delay 158 upon 90% correct or better performance, and was reduced 1-s (to a minimum of 1-s) upon 159 performance of less than 90% correct. Once 90% correct performance or better was achieved in 160 one session at the 5-s delay, training was complete and experimental testing began. were identified using the soma as the counting target and numbers were estimated using the 278 optical fractionator probe following the process described in West et al. (1991) . Pilot studies 279 were performed to determine appropriately sized sampling grids and counting frames. Six to 280 seven sections were used for each animal. Both cresyl and mCherry-stained tissue were 281 counted using a x40 oil-immersion objective lens within a counting frame of 100 x 100 x 10 µm 3 282 with the dissector top guard volume extended 1 µm below the tissue section surface. The 283 sampling grid for cresyl cells was 700 x 700 µm 2 and the sampling grid for mCherry-positive 284 cells was 400 x 400 µm 2 . The cell body was used as the counting object for cells that fell within 285 the dissector or across its inclusion planes. Neurons were differentiated from glia by cell morphology, identified with the cresyl violet stain, and the presence of a well-defined nucleolus. 287
Coefficients of error were calculated for each region to ensure minimal variance due to 288 sampling. 289
290
Representative histological images are shown in Figure 1 . mCherry immunostaining was 291 patchy, as expected. We did not quantify mCherry staining outside of the dlPFC; however, we 292 observed some staining outside the region of interest in four out of the five cases. These stained 293 cells may be attributed to unintended deeper penetrations during surgery as a result of the the 294 handheld syringe technique. Cases A, B, and Z showed small patches of mCherry-positive cells 295 in medial prefrontal cortex, mostly localized around the cingulate sulcus. Cases A and P showed 296 several instances of stained cells in orbital prefrontal cortex, concentrated around the medial 297 orbital sulcus region. No case exhibited staining in thalamus and posterior parietal cortex. 298
Although four out of the five cases demonstrated variable degrees of ectopic staining, there was 299 no obvious relationship between this ectopic staining and behavioral effects of CNO 300 administration, with ectopic staining being present in the same cortical regions in both monkeys 301 that showed effects of CNO administration post-surgery and those that did not. 302 303
Statistical Analysis 304
Because of variability across monkeys in the effect of CNO on performance after surgery, and 305 because we were limited in the number of test sessions we could carry out with each monkey 306 due to constraints on our supply of CNO and the large quantity of drug required to generate a 307 sufficient dose for each behavioral test session, we adopted a case study-type approach to data 308 analysis. For each monkey, we determined first the impact of vehicle injections and pre/post 309 surgery on performance, using a 2 x 2 ANOVA on percent correct performance across vehicle 310 and no-injection test sessions before and after surgery, treating each session as a unit of 311 analysis within each monkey. No monkey showed an effect of vehicle injection relative to 312 baseline sessions without vehicle injection, and for only one monkey (case Z) did performance 313 differ between pre-and postoperative testing (performance was better after surgery than 314 before). We used the single-case t-test approach of Crawford and Howell (1998) to evaluate 315 each drug test session compared to postoperative vehicle injection sessions for each monkey, 316 because the number and timing of drug injection test sessions varied across monkeys as we 317 accumulated data and our experimental protocol evolved based on communication with other 318 research groups that were carrying out studies with DREADDs in monkeys concurrently with 319 ours. We evaluated significant impairments in drug testing sessions as one-tailed p-values < .05 320 generated from each t-test. Because we expected only impairments following drug 321 administration a priori, we judged one-tailed tests to be appropriate. In any case, the evaluation 322 of statistical significance of any individual test session is only a proxy for the absolute magnitude 323 of the drug effect in terms of an increase in errors committed during the test session, which is 324 readily apparent from the raw behavioral data. 325
326
To adjust for baseline differences in performance, we determined an aggregate "deficit score" 327 based on postoperative DREADD receptor activation (Croxson et al., 2012) . This score was 328 calculated as a percent of maximal deficit in the spatial delayed response task, providing a 329 single score characterizing each monkey's behavioral impairment. We computed the correlation 330 between this behavioral deficit score and the percentage of neurons in each monkey's dlPFC 331 that was transduced by DREADD receptors, based on the stereological quantification. 332 333
Results 334
The effects of DREADD-mediated dlPFC inhibition on spatial working memory 335 A summary of behavioral data for all five cases can be found in Table 2 . Two monkeys 336 demonstrated robust impairments in the spatial working memory task after injection of CNO 337 (Cases B and P), one monkey demonstrated moderate impairment (Case T), and two monkeys 338 showed no difference in spatial working memory function after CNO administration (Cases A 339 and Z). It is interesting in Cases B and P that they were unimpaired during their final CNO test 340 session, perhaps suggesting that with repeated dosing they were able to compensate for the 341 impact of temporary neuronal inhibition following systemic CNO. Mean performance for vehicle 342 and CNO sessions for each monkey is shown in Figure 2 , both across all sessions in each 343 condition (Figure 2A) and broken down by delay (Figure 2B) . Given the limited number of total 344 trials at each delay, we did not carry out data analyses at each delay individually, but it is 345
interesting that case T appears to show deficits only at the longest delay tested. 346
347
The effects of CNO on behavior 348
As a control measure for the effects of CNO on behavior, we obtained data on CNO injections 349 prior to AAV injection surgery in two cases (one session each in cases P and Z). Case P, who 350 showed marked effects of 20 mg/kg CNO after surgery, showed no effect of 20 mg/kg CNO 351 preoperatively (70.8% correct 73.4% correct on vehicle, t = -0.33, p = 0.37. Case Z, who did not 352
show effects of 20 mg/kg CNO after surgery, actually did worse on his pre-surgery CNO test 353 compared to vehicle performance, 83.3% correct vs 95.8% correct on vehicle, t = -2.14, p = 354 0.029, although this comparison is complicated by overall better postoperative performance 355 compared to preoperative performance in this monkey, which elevates his mean vehicle score. 356
In any case, this monkey showed no impairments in two further 20 mg/kg CNO sessions done 357 after surgery, arguing against general nonspecific effects of CNO on behavior. Case T had one 358 session with Compound 21 preoperatively, and scored 96% correct, suggesting Compound 21 359 also had no discernible behavioral effect in the absence of DREADD expression. 360
361
The relationship between DREADD receptor transduction in dlPFC and spatial working memory 362 performance We conducted unbiased stereological counting on histological sections from the dlPFC of each 364 animal to determine the relationship between behavioral performance in the spatial delayed 365 response task and the proportion of neurons transduced with inhibitory DREADD receptor. 366
Monkeys that demonstrated behavioral impairments showed an increased level of mCherry 367 staining compared to monkeys that demonstrated no behavioral change after CNO injection. We 368 found that there was a significant positive correlation between percent of positive mCherry-369 immunolabeled neurons in the dlPFC and performance on the spatial delayed response task 370 after CNO administration calculated as a percent deficit score [(mean baseline -mean 371 CNO)/(mean baseline -chance)], r = 0.8745, p = .0196, illustrated in Figure 3 . 372 373 Discussion 374
In some monkeys who received hM4Di DREADD AAV injections into the dlPFC, we were able 375 to obtain a reliable behavioral deficit in a spatial working memory task following systemic 376 injections of CNO. In monkeys where we examined CNO injections preoperatively, no impact on 377 behavior was seen. There was a monotonic relationship between the extent of DREADD 378 receptor transduction within the dlPFC and the magnitude of behavioral impairment following 379 DREADD receptor activation. Thus, there is a biological basis to apparently stochastic effects of 380 DREADD transduction in rhesus monkeys. In the two monkeys with the largest behavioral 381 deficits following DREADD receptor activation, only ~3% of neurons within the dlPFC were 382 transduced with DREADD receptors. These findings have implications for the implementation of 383 chemogenetic approaches in nonhuman primates, as well as for the neurophysiology of 384 cognitive functions of the prefrontal cortex. 385
386
Our goal in initiating this study was to determine, with a simple behavioral task dependent on a 387 cortical area with a straightforward surgical approach, whether we could achieve a substantial 388 behavioral deficit by activation of hM4Di DREADDs on par with what could be achieved by a 389 cortical ablation or neurotoxic lesion. This would be a critical prelude to using chemogenetic 390 methods in studies where the consequence of neuronal inhibition (or activation) would be less 391 clearly determined a priori. We were only partially successful in accomplishing this goal. In two 392 cases (B and P) we achieved substantial behavioral impairments with DREADD receptor 393 activation, but in the other three cases, effects were equivocal. The basis of this variability was 394 clearly related to the extent of DREADD receptor transduction within the dlPFC. Nagai et al. 395 (2016) reported a similar phenomenon, where by in cases where systemic CNO failed to 396 produce a behavioral deficit in their reward sensitivity task, they also did not observe significant 397 displacement of 11 C-clozapine in PET scans following CNO administration. Because they made 398 this determination in vivo, they were able to make additional AAV injections in an effort to 399 increase DREADD receptor expression and thereby achieve behavioral effects of CNO 400 administration. Extent of DREADD receptor transduction appeared to be unrelated to surgical 401 parameters such as number of injections in each case or lot of viral vector used. We did not 402 determine the presence of AAV neutralizing antibodies in our monkeys prior to surgery; these 403 have been reported after AAV injections into the central nervous system for delivery of 404 optogenetic constructs (Mendoza et al., 2017) , although it is not clear whether the presence of 405 neutralizing antibodies would impede transduction by AAV (Gray et al., 2013) . 406 407 Both monkeys that showed marked behavioral impairments after 20 mg/kg CNO appeared to 408 adapt, with performance in each monkey's final test session at this dose not differing 409 significantly from baseline. Perhaps with a relatively small population of neurons in dlPFC being 410 functionally silenced by systemic CNO, the monkeys were able to compensate after repeated 411 behavioral testing on the delayed response task under CNO. This could not have been related 412 to level of DREADD expression as a function of time post-transduction, because the interval 413 between surgery and test for case B was quite long and was much briefer for case P. It has 414 also been shown that significant desensitization of DREADDs apparently does not occur in vivo 415 (Roth, 2016; Roman et al., 2016) . Nonetheless, this may suggest some additional limitations on 416 using functional silencing with chemogenetic techniques as a tool to investigate behavioral 417 deficits after inhibitions of specific populations of neurons. 418
419
Although CNO is present in the cerebrospinal fluid (CSF) in monkeys (Eldridge et al., 2015; 420 Raper et al., 2017) , it has also become apparent recently that CNO is actively transported out of 421 brain parenchyma by P-glycoprotein (Raper et al., 2017) . Thus CSF concentrations may not 422 reflect CNO availability at neuronally expressed DREADD receptors. Moreover, conversion of 423 CNO to clozapine occurs in monkeys, producing concentrations of clozapine sufficient to bind to 424 DREADD receptors (Raper et al., 2017) . A recent study in rodents suggests that the mechanism 425 of hM3/hM4 DREADD receptor activation is exclusively via conversion of CNO to clozapine 426 (Gomez et al., 2017) . We saw no effect of CNO injections on behavior in our monkeys prior to 427 DREADD receptor expression so we do not think positive effects of CNO, where observed, are 428 explained merely by clozapine interaction with non-DREADD receptors. It remains a logical 429 possibility that individual differences in CNO penetration of the central nervous system, or of 430 conversion of CNO to clozapine, influence the behavioral effectiveness of DREADD receptor 431 activation. Because we did not determine CSF levels of CNO/clozapine in our monkeys, we 432 cannot address this possibility. As suggested by Gomez et al. (2017) , future studies might use 433 low doses of clozapine, that do not produce behavioral effects on their own, as DREADD 434 actuators rather than CNO. There is an alternative non-CNO actuator, compound 21 (Chen et 435 al., 2015) that is a potential alternative to CNO/clozapine. We only had the opportunity to carry 436 out limited experiments with compound 21 in this study, but it appears comparable to CNO in 437 potency. Another possibility for future studies is using an alternative DREADD receptor system 438 such as that based on modification of the kappa opioid receptor (KORD-DREADD; (Vardy et al., 439 2015) . However, this approach has limited application in monkeys at the moment because the 440 limited solubility of the KORD-DREADD ligand salvanorin B makes dosing impractical.
Despite the technical challenges encountered, we were able to impair spatial delayed response 442 performance, a task dependent on intact dlPFC, by DREADD receptor activation in monkeys in 443 which ~3% of prefrontal neurons were transduced with the hM4Di DREADD receptor. This 444 implies that inhibition of a relatively small fraction of dlPFC neurons is sufficient to produce 445 substantial behavioral deficits in the delayed response task. We were surprised by this finding, 446 expecting before we initiated these experiments that we would need to affect much greater 447 proportions of cortical neurons before behavioral impairments would become apparent. It is 448 possible that the nature of neural coding in the spatial delayed response task, hypothesized to 449 involve competition among microcircuits encoding possible goal locations (Arnsten et al., 2012) 450 makes it particularly vulnerable to disruption of a small number of neurons in the network. This 451 may not be the case for the involvement of other cortical/subcortical structures, in terms of the 452 extent of disruption that would be required to impair behavior. For example, spatial navigation 453 functions of the hippocampus apparently can be supported with only a small "minislab" of intact 454 hippocampal tissue (Moser et al., 1995) , suggesting that a much greater degree of transduction 455 within the hippocampus would be required to produce behavioral deficits via an inhibitory 456 DREADD receptor mechanism. Purely as an experimental design consideration, it will be 457 critical, as in other lesion/inactivation studies of behavior, to take advantage of control tasks 458 whose sensitivity to target structures is known, as well as dissociation methodology (Olton, 459 1991) to guard against errors in interpretation of functional deficits following neuronal 460 inactivation (or activation). It is critical moving forward with these chemogenetic techniques that 461 we proceed with both optimism and caution and support future findings with rigorous means of 462 quantification to better verify these methods. As these methods develop, it will be important to 463 continue to evaluate them in parallel with other approaches to interfering with neuronal activity, 464
including pharmacological inactivations and permanent lesions, in order to obtain convergent 465 evidence on the functions of neural systems for complex behavior in the primate brain. 466 
